

For prescribers licensed in Colorado



Pursuant to the Colo. Rev. Stat. § 12-42.5-308 (2019), GSK makes the following pricing disclosure to individuals licensed by the State of Colorado to prescribe prescription drugs. The price(s) below represent the wholesale acquisition cost (or WAC), also known as list price, for BENLYSTA¹ as of the date of this notice.

WAC is the listed price to wholesalers not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. Listed price may not represent prices charged to other customers. For more information on the prices that patients pay, please check with the patient's healthcare provider.

Where available, GSK also identifies up to three (3) generic prescription drugs from the same therapeutic class as the GSK product listed. Please note that the identification of any generic product in the table below does not imply that that product is preferred, available commercially, interchangeable with any other product, nor is it intended to be a claim regarding the efficacy or safety of that product.

Prices are subject to change without notice. This notice is not a solicitation and does not constitute an offer to sell any GSK product.

WAC for BENLYSTA (belimumab) INJ as of July 2025

<u>GSK Product Name w/ Strength</u>	<u>NDC or UPC</u>	<u>Pkg Size</u>	<u>WAC (Pkg)</u>	<u>Generic</u>	<u>Generic</u>	<u>Generic</u>
BENLYSTA INJ 120MG	49401-0101-01	1 EA/5-mL vial for IV	\$647.45	N/A	N/A	N/A
BENLYSTA INJ 200MG/ML	49401-0088-35	4 ML/pre-filled autoinjector for SC	\$4,987.78	N/A	N/A	N/A
BENLYSTA INJ 200MG/ML	49401-0088-47	4 ML/pre-filled syringe for SC	\$4,987.78	N/A	N/A	N/A
BENLYSTA INJ 400MG	49401-0102-01	1 EA/20-mL vial for IV	\$2,158.01	N/A	N/A	N/A

Prices appearing on this form were obtained from GSK data on file as of July 2025.

To access the full Prescribing Information for the GSK product, please visit us at
<https://gsksource.com/pharma/content/gsk/source/us/en/brands.html?type=Prescription>

¹ Trademarks are owned by or licensed to the GSK group of companies

For prescribers licensed in Connecticut



Pursuant to Connecticut Public Act No. 23-171 (2023), GSK makes the following pricing disclosure to a practitioner or pharmacist licensed by the State of Connecticut to prescribe prescription drugs. The price(s) below represent the wholesale acquisition cost (or WAC), also known as the list price, for BENLYSTA¹ as of the date of this notice.

WAC is the listed price to wholesalers not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. Listed price may not represent prices charged to other customers. For more information on the prices that patients pay, please check with the patient's healthcare provider.

As required by Act No. 23-171, where available, GSK also provides information on the variation efficacy of the prescription drug to the prescribing practitioner or pharmacist based on the dose and quantity of that drug to marketed to different racial and ethnic groups.

Prices are subject to change without notice. This notice is not a solicitation and does not constitute an offer to sell any GSK product.

WAC for BENLYSTA (belimumab) INJ as of July 2025

<u>GSK Product Name w/ Strength</u>	<u>NDC or UPC</u>	<u>Pkg Size</u>	<u>WAC (Pkg)</u>	<u>Variation Efficacy Information (If Available)</u>
BENLYSTA INJ 120MG	49401-0101-01	1 EA/5-mL vial for IV	\$647.45	As required by Act No. 23-171, if available, GSK provides information on the variation efficacy of prescription drugs marketed to different racial and ethnic groups to the prescribing practitioner or pharmacist. For more information on Benlysta, please refer to our prescribing information or contact Medical Information 1-877-GSK-MI4U for more information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
BENLYSTA INJ 200MG/ML	49401-0088-35	4 ML/pre-filled autoinjector for SC	\$4,987.78	As required by Act No. 23-171, if available, GSK provides information on the variation efficacy of prescription drugs marketed to different racial and ethnic groups to the prescribing practitioner or pharmacist. For more information on Benlysta, please refer to our prescribing information or contact Medical Information 1-877-GSK-MI4U for more information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
BENLYSTA INJ 200MG/ML	49401-0088-47	4 ML/pre-filled syringe for SC	\$4,987.78	As required by Act No. 23-171, if available, GSK provides information on the variation efficacy of prescription drugs marketed to different racial and ethnic groups to the prescribing practitioner or pharmacist. For more information on Benlysta, please refer to our prescribing information or contact Medical Information 1-877-GSK-MI4U for more information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
BENLYSTA INJ 400MG	49401-0102-01	1 EA/20-mL vial for IV	\$2,158.01	As required by Act No. 23-171, if available, GSK provides information on the variation efficacy of prescription drugs marketed to different racial and ethnic

¹ Trademarks are owned by or licensed to the GSK group of companies



				groups to the prescribing practitioner or pharmacist. For more information on Benlysta, please refer to our prescribing information or contact Medical Information 1-877-GSK-MI4U for more information. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
--	--	--	--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prices appearing on this form were obtained from GSK data on file as of July 2025.

To access the full Prescribing Information for the GSK product, please visit us at <https://gsksource.com/pharma/content/gsk/source/us/en/brands.html?type=Prescription>